NCT00006227 · OUTCOME

Progression-free Survival

Paclitaxel in Treating Patients With Ovarian Stromal Cancer · Source last updated 2020-03-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: Months
Interval / dispersion: 80% Confidence Interval
Time frame: The period from study entry until disease progression, death or date of last contact

What was measured

Duration of progression free survival (median) (months)

Groups in this outcome

Treatment (Paclitaxel)

Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Paclitaxel: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Paclitaxel)	31

Reported measurements

Source class 1

Values in Months · Interval/dispersion: 80% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Treatment (Paclitaxel)	10.0	Not reported	6.0	19.6	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
6.0
upper Limit
19.6
value
10.0

denoms

counts
group Id
OG000
value
31
units
Participants

description

Duration of progression free survival (median) (months)

dispersion Type

80% Confidence Interval

groups

description
Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Paclitaxel: Given IV
id
OG000
title
Treatment (Paclitaxel)

param Type

MEDIAN

reporting Status

POSTED

time Frame

The period from study entry until disease progression, death or date of last contact

title

Progression-free Survival

type

SECONDARY

unit Of Measure

Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice